Positions

NIH T32 Postdoctoral Fellow
Lester and Sue Smith Breast Center
Baylor College of Medicine
Houston, TX, US

Education

BS from Baylor University
Biology
PhD from Baylor College of Medicine
Translational Biology and Molecular Medicine

Honors & Awards

SABCS Basic Science Scholar Award
3rd Place Poster Award
Translational Biology & Molecular Medicine Retreat and Research Conference Annual Retreat
2nd Place Poster Award
Department of Medicine Annual Symposium
1st Place Poster Award
Alumni Reunion Poster Competition
2nd Place Oral Presentation Award
Lester and Sue Smith Breast Center Annual Breast Cancer Research & Education Program
1st Place Oral Presentation Award
Translational Biology & Molecular Medicine Retreat and Research Conference Annual Retreat
Director's Award for Best Scientific Paper
Translational Biology & Molecular Medicine Retreat and Research Conference Annual Retreat
Excellence in Leadership Award for Educational Outreach
Translational Biology & Molecular Medicine Program

Professional Interests

  • Endocrine Therapy Resistance
  • Estrogen Receptor Alpha (ESR1) Chromosomal Rearrangements / ESR1 Fusions
  • Clinical Proteogenomics
  • Computational Approaches and Synthetic Lethality in Cancer

Professional Statement

Predicting synthetic lethality, where the inactivity of two genes leads to cell death, is a promising approach to identify therapeutic vulnerabilities in many cancer types. More recently, incorporation of large-scale genomics data together with traditional RNAi screens have revealed cancer synthetic lethality networks that have prognostic and therapeutic implications. Our lab is developing computational approaches that includes proteogenomics analyses to predict synthetic lethal drug targets across various cancer types that will generate testable therapeutic hypotheses by leveraging large-scale proteomics and phospho-proteomics data from colon, breast, ovarian, and uterine human cancer data sets, in addition to patient-derived xenografts, to complement genomic mutation, amplification, and overexpression data to predict synthetic lethality and drug response. By integrating phospho-level data, this approach will potentially refine the determinants of gene inactivation status and more robustly nominate clinically actionable synthetic lethal targets than examining genomic data alone.

Selected Publications

Memberships

American Association for Cancer Research

Funding

T32 Postdoctoral Fellowship
- #T32CA203690
Grant funding from NIH

Professional Development

Functionally diverse ESR1 gene fusions drive endocrine resistance is estrogen receptor positive breast cancer
Sponsor: San Antonio Breast Cancer Symposium
Poster Discussion
Estrogen receptor gene fusions drive endocrine therapy resistance in estrogen receptor positive breast cancer
Sponsor: American Association for Cancer Research Annual Meeting
Oncogenes and Tumor Suppressors Minisymposium
ESR1 gene fusions drive endocrine resistance and metastasis in breast cancer
Sponsor: San Antonio Breast Cancer Symposium
Spotlight Poster Discussion